Comparative Pharmacology
Head-to-head clinical analysis: ANTHIM versus ARZERRA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANTHIM versus ARZERRA.
ANTHIM vs ARZERRA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Oblimersen is an antisense oligonucleotide that inhibits the production of Bcl-2 protein, promoting apoptosis in cancer cells.
Ofatumumab is a fully human monoclonal antibody that binds specifically to the CD20 molecule on B lymphocytes, resulting in complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) of CD20+ cells.
800 mg IV over 90 minutes, then 400 mg IV over 90 minutes at 2 and 4 weeks post-first dose.
ARZERRA (ofatumumab) for chronic lymphocytic leukemia (CLL): Initial dose 300 mg IV, then 1 week later 2000 mg IV weekly for 6 doses, then 2000 mg IV every 4 weeks for up to 4 additional doses. For relapsed CLL: 300 mg IV followed by 1000 mg IV on day 8, then 1000 mg IV on day 15 and day 22 of cycle 1, then 1000 mg IV on day 1 of cycles 2-6 (28-day cycles). Premedicate with acetaminophen, antihistamine, and corticosteroid.
None Documented
None Documented
Terminal elimination half-life: approximately 21 days (range 12–31 days); supports monthly dosing for post-exposure prophylaxis
Mean terminal elimination half-life after first dose is approximately 14 days (range 7–21 days) and increases with repeated dosing due to target-mediated clearance saturation; at steady state, half-life is ~24 days.
Renal: approximately 50% as unchanged drug; biliary/fecal: minimal (<10%)
Arzerra (ofatumumab) is eliminated primarily via the reticuloendothelial system and catabolism; renal excretion is minimal (<1% of dose as intact antibody). Biliary/fecal excretion has not been characterized, but as a monoclonal antibody, it is not significantly excreted in urine or feces.
Category C
Category C
Monoclonal Antibody
Antineoplastic, Monoclonal Antibody